Clearbridge Investments LLC Has $54.17 Million Stock Position in Rhythm Pharmaceuticals, Inc. $RYTM

Posted by George Bondi on Jun 9th, 2026

Clearbridge Investments LLC raised its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 4.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506,109 shares of the company’s stock after purchasing an additional 21,377 shares during the period. Clearbridge Investments LLC’s holdings in Rhythm Pharmaceuticals were worth $54,174,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in RYTM. Vanguard Group Inc. raised its position in Rhythm Pharmaceuticals by 39.2% during the third quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after purchasing an additional 1,407,313 shares in the last quarter. Alliancebernstein L.P. raised its position in Rhythm Pharmaceuticals by 1,493.8% during the third quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock valued at $98,938,000 after purchasing an additional 918,212 shares in the last quarter. Capital Research Global Investors acquired a new position in Rhythm Pharmaceuticals during the third quarter valued at approximately $60,417,000. Jennison Associates LLC raised its position in Rhythm Pharmaceuticals by 123.2% during the fourth quarter. Jennison Associates LLC now owns 918,567 shares of the company’s stock valued at $98,323,000 after purchasing an additional 507,017 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Rhythm Pharmaceuticals by 51.6% during the third quarter. JPMorgan Chase & Co. now owns 1,188,069 shares of the company’s stock valued at $119,983,000 after purchasing an additional 404,510 shares in the last quarter.

Rhythm Pharmaceuticals Stock Down 0.5%

Shares of Rhythm Pharmaceuticals stock opened at $85.93 on Tuesday. Rhythm Pharmaceuticals, Inc. has a twelve month low of $60.70 and a twelve month high of $122.20. The stock has a market cap of $5.89 billion, a price-to-earnings ratio of -27.45 and a beta of 1.92. The company’s fifty day moving average is $87.53 and its 200 day moving average is $96.69.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.03. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. The company had revenue of $60.11 million for the quarter, compared to analysts’ expectations of $55.78 million. During the same quarter in the previous year, the firm posted ($0.81) earnings per share. Rhythm Pharmaceuticals’s revenue for the quarter was up 83.8% on a year-over-year basis. As a group, equities analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -3.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Guggenheim boosted their price objective on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Telsey Advisory Group set a $143.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, March 12th. Wells Fargo & Company boosted their price objective on shares of Rhythm Pharmaceuticals from $143.00 to $144.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Bank of America lowered their price objective on shares of Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Finally, Morgan Stanley decreased their target price on shares of Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.81.

Read Our Latest Stock Report on RYTM

About Rhythm Pharmaceuticals

(Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.